Clinical stage drug discovery & development company focusing on rare genetic diseases
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
85
NCT04908462
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 8, 2021
Completion: Jun 20, 2022
NCT06114329
Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease
Phase: Phase 2
Start: Oct 25, 2023
Completion: Jun 30, 2026
Loading map...